MDR Makes EU ‘Much Less Attractive’ For Start-Ups, Says Medtronic EMEA Chief
The fragility of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.
The fragility of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.